Skip to content

Imaging and Surveillance

TL;DR — TAA management is built on serial diameter measurements, yet the measurement itself is the weakest link. ECG-gated CT or MRI with double-oblique (orthogonal) reformats is the reference standard; TTE sees only the root and proximal ascending aorta but supplies the historical normal values. Conventions differ by modality (CT/MRI: inner-edge to inner-edge; echo: leading-edge to leading-edge at end-diastole), and the 95% limits for a repeat measurement by the same reader reach ±2.4–5.2 mm on gated CT — the same order as several years of aneurysm growth (0.10–0.12 cm/yr), and larger than the 2–3 mm that separates "watch" from "operate" at decision thresholds. The 2022 ACC/AHA guideline therefore standardizes technique, demands same-modality/same-technique comparison before acting on apparent growth, and sets surveillance intervals of 6–24 months by size. Screening is indicated for first-degree relatives of patients with root/ascending aneurysm or dissection — about 1 in 4 to 1 in 3 screened relatives in nonsyndromic families carries disease. The biggest unsolved problem: annual growth is usually smaller than measurement error, so "growth" on a single follow-up scan is often noise.

Modality comparison

Modality What it sees Resolution / gating Radiation & contrast Main role Key limitations
TTE Aortic root, proximal ascending aorta; aortic valve anatomy/function Good temporal resolution; images root in standardized long-axis views; end-diastolic leading-edge convention None First test at diagnosis (COR 1, C-LD); serial root surveillance (esp. Marfan/BAV); source of age/sex/BSA-adjusted normal values Cannot reliably see mid-ascending, arch, or descending aorta; acoustic-window dependent (Isselbacher 2022, PMID 36322642; Goldstein 2015, PMID 25623219)
TEE Nearly whole thoracic aorta (blind spot at distal ascending/proximal arch); superb valve detail High spatial + temporal resolution None (sedation required; semi-invasive) Acute aortic syndromes, intraoperative assessment, valve repair planning Invasive; not a surveillance tool (Isselbacher 2022, PMID 36322642; Goldstein 2015, PMID 25623219)
ECG-gated CT/CTA Entire aorta + branches Highest spatial resolution; fast; gating removes root/ascending motion artifact and reduces measurement variability Ionizing radiation; iodinated contrast (non-contrast possible for diameter follow-up) Reference standard for full-aorta anatomy, preop planning, post-TEVAR surveillance Radiation with lifelong serial imaging; contrast nephrotoxicity/allergy (Isselbacher 2022, PMID 36322642)
MRI/MRA Entire aorta; wall and lumen; flow (4D-flow research) Good spatial (inferior to CT), gated 3D datasets allow precise repeatable measurement No radiation; can be done without gadolinium Preferred for lifelong serial imaging in young patients and congenital aortopathy; alternative to CT after TEVAR Longer acquisition; metal artifact; availability (Isselbacher 2022, PMID 36322642)

Non-gated CT deserves its own warning: pulsation artifact at the root/ascending aorta both blurs the wall and can simulate dissection; gating "decreases motion artifact and improves edge depiction... with diminished measurement variability" (Isselbacher 2022, PMID 36322642).

Measurement technique: conventions and the reproducibility problem

The 2022 ACC/AHA measurement conventions (COR/LOE in parentheses)

Convention Detail
CT/MRI edge convention (1, C-EO) Inner-edge to inner-edge, ECG-synchronized; if wall abnormality (atherosclerosis, thickening — more common distally), report outer-edge to outer-edge (Isselbacher 2022, PMID 36322642)
Root measurement (1, C-EO) Maximum sinus-to-sinus diameter; report multiple measurements if root asymmetric (Isselbacher 2022, PMID 36322642)
Plane Perpendicular to the long axis (axis of blood flow); from 3D datasets, create multiplanar reformats orthogonal to the flow axis at each level (the "double-oblique short axis") — oblique cuts overestimate diameter where the aorta curves (Isselbacher 2022, PMID 36322642)
Echo convention (2a, C-EO) Leading-edge to leading-edge at end-diastole, perpendicular to flow; inner-edge to inner-edge may also be considered, particularly on short axis (Isselbacher 2022, PMID 36322642)
Indexing (2a, C-LD) Report root/ascending diameter indexed to height or BSA to aid risk assessment (Isselbacher 2022, PMID 36322642)

Two conventions coexist historically because the large TTE literature that generated normal limits (adjusted for age, sex, body size) measured the root at end-diastole leading-edge to leading-edge, whereas CT/MRI practice settled on inner-edge; there is still no single accepted standard across modalities (Isselbacher 2022, PMID 36322642). Practical consequences:

  • Leading-edge includes the near wall; inner-edge excludes both walls — so echo leading-edge values run systematically larger than CT/MRI inner-edge values by roughly one wall thickness; the guideline explicitly warns that "discrepancies in measurement can occur when comparing different imaging modalities or even when using the same modality... with and without contrast" (Isselbacher 2022, PMID 36322642). The best-quantified systematic offset is within CT itself: centerline analysis reads consistently larger than double-oblique short axis, with 95% limits of ±1.8–3.2 mm for the between-method difference — i.e., method choice alone moves a reading by the 2–3 mm that separates surveillance from surgery (Quint 2013, PMID 22864960).
  • Systole vs diastole: the aorta is pulsatile; echo convention fixes end-diastole, while CT/MRI gating reconstructs a chosen cardiac phase — another few-millimeter lever if phases differ between studies (Isselbacher 2022, PMID 36322642).

Quantified reproducibility

On gated CT of the proximal aorta, using double-oblique short-axis technique, mean intraobserver differences were small (−0.3 to 0.6 mm) but the 95% CI for a repeat measurement was ±2.4 to ±5.2 mm depending on level and reader; semiautomatic centerline analysis performed similarly (±2.0 to ±4.6 mm) and gave systematically larger values than double-oblique (95% CI of the difference ±1.8–3.2 mm); significant interobserver differences existed for both methods, and neither was clearly superior (Quint 2013, PMID 22864960).

Why 2–3 mm matters: elective surgery hinges on fixed cut-points (5.5 cm; 5.0 cm at experienced centers; 4.5 cm in Marfan with risk features — see guidelines). A true 5.3 cm aorta measured at 5.6 cm (well within the 95% CI of a single reading) crosses the operative threshold; the reverse error postpones an indicated repair. The 2022 guideline's answer is procedural: standardized technique, same laboratory, side-by-side re-measurement of prior studies, and growth confirmed by "tomographic imaging" — ideally gated CT/MRI with centerline technique — before surgery is offered for growth alone (Isselbacher 2022, PMID 36322642).

The growth-measurement-error problem

Mean expansion of unrepaired TAA is slow: 0.10 cm/yr in the Yale natural-history cohort of 721 patients (Davies 2002, PMID 11834007), 0.12 cm/yr in the earlier 230-patient series (Coady 1997, PMID 9081092), 0.19 cm/yr for BAV vs 0.13 cm/yr for tricuspid-valve ascending aneurysms in a 514-patient comparison (Davies 2007, PMID 17383337). Growth accelerates with diameter but even "rapid" growth (≥0.3 cm/yr) is close to single-measurement error (±2.4–5.2 mm 95% CI; Quint 2013, PMID 22864960).

Consequences:

  • A one-interval "jump" of 3–4 mm is as likely to be technique (different modality, contrast status, plane, phase, reader) as biology; the guideline requires growth ≥0.3 cm/yr in 2 consecutive years or ≥0.5 cm in 1 year (COR 1, C-LD) before growth alone triggers surgery, and specifies "when measured similarly with same technique" for the BAV growth criterion (Isselbacher 2022, PMID 36322642).
  • Published growth rates from cohorts with sparse, mixed-modality imaging inherit this noise; regression-based estimates over many studies (as in the Yale database with 3,115 imaging studies across 721 patients) mitigate but do not remove it (Davies 2002, PMID 11834007).
  • For research, this is the core argument for centerline, gated, single-modality protocols and for motion-robust endpoints (volume, length; see aortic length under risk stratification, Wu 2019, PMID 31526537).

Surveillance intervals

2022 ACC/AHA scheme for unoperated dilation/aneurysm (all 2a unless noted):

Situation Recommendation
New diagnosis of dilated thoracic aorta TTE at diagnosis (COR 1, C-LD) for valve + root; CT or MRI at diagnosis (2a, C-LD) to define whole-aorta anatomy (Isselbacher 2022, PMID 36322642)
First follow-up Repeat imaging (TTE, CT, or MRI as anatomy dictates) at 6–12 months to establish growth rate (2a, C-LD) (Isselbacher 2022, PMID 36322642)
Stable Surveillance every 6–24 months depending on diameter (2a, C-LD) (Isselbacher 2022, PMID 36322642)
Turner syndrome (adults, no risk factors, ASI ≤2.3 cm/m²) TTE or MRI every 2–3 years; ASI >2.3 cm/m² → at least annual (COR 1, C-EO) (Isselbacher 2022, PMID 36322642)
After open repair, no residual aortopathy CT/MRI within 1 year, then every 5 years (2a, B-NR); annual if residual aortopathy or abnormal findings (2a, C-EO) (Isselbacher 2022, PMID 36322642)
After TEVAR CT at 1 month and 12 months, then annually (COR 1, B-NR); MRI as radiation-sparing alternative (2a, B-NR) (Isselbacher 2022, PMID 36322642)

In Marfan trials the aortic root grew only 1–1.5 mm over 3 years on therapy — annual TTE is standard there, with more frequent imaging for rapid growth or larger aneurysms (Isselbacher 2022, PMID 36322642). Details of size thresholds and the size-based logic behind interval choice: risk stratification, guidelines.

Incidental detection and screening: who should be imaged

TAA is usually silent; most are found incidentally on imaging done for other reasons. The population context explains both the detection problem and the screening rationale: in a 3,573-subject multiethnic community sample (MESA, MRI), mean ascending diameter was 3.2 ± 0.4 cm; only 2.6% of the population measured 4.0–4.4 cm and 0.22% ≥4.5 cm (Paruchuri 2015, PMID 25997607). There is no population-wide TAA screening program (contrast AAA ultrasound screening); detection therefore relies on incidental findings plus targeted screening of high-risk groups.

Who gets screened (2022 ACC/AHA):

Group Recommendation
First-degree relatives of patients with aortic root/ascending aneurysm or aortic dissection (no known family history or pathogenic variant) Screening aortic imaging (COR 1, C-LD) (Isselbacher 2022, PMID 36322642)
Families with identified pathogenic/likely pathogenic variant Cascade genetic testing of biological relatives (COR 1); imaging of carriers (Isselbacher 2022, PMID 36322642)
First-degree relatives of BAV patients TTE screening reasonable (2a, B-NR) to look for BAV and root/ascending dilation (Isselbacher 2022, PMID 36322642)
Acute type A dissection patients Record root/ascending diameter in the operative note to inform management of relatives (COR 1, C-EO) (Isselbacher 2022, PMID 36322642)

Screening yield is high in nonsyndromic thoracic aortic disease families: across 53 studies (2,696 screened relatives), newly affected individuals were found in 33% of first-degree, 24% of second-degree, and 15% of third-degree relatives; no study had evaluated the predictive accuracy or cost-effectiveness of a formal screening program (Mariscalco 2018, PMID 30371227). In the prospective REST feasibility study (16 probands, 54 relatives; imaging + whole-exome sequencing; NCT03861741), mild-to-moderate aortic dilation was found in 24% of relatives and some form of further phenotyping or secondary prevention was indicated in 54–68%, without measurable psychological harm at 3 months (Abbasciano 2022, PMID 35383466). Genetics of familial disease: genetics of TAA; BAV-specific surveillance: bicuspid aortopathy.

Open questions

  • Can measurement error be beaten by software rather than protocol? Automated centerline segmentation reduced but did not eliminate interobserver spread and introduced a systematic offset vs double-oblique reads (±1.8–3.2 mm) (Quint 2013, PMID 22864960); no method has demonstrated the sub-millimeter reproducibility that annual growth tracking actually requires (growth 0.10 cm/yr; Davies 2002, PMID 11834007).
  • What is the correct conversion when a patient's surveillance switches modality (echo leading-edge ↔ CT inner-edge)? The 2022 guideline acknowledges systematic inter-modality differences but provides no validated correction factor (Isselbacher 2022, PMID 36322642).
  • Should surveillance endpoints move beyond maximal diameter (volume, length, shape)? Ascending length grows ~0.18 cm/yr and is nearly immune to the acute 18% diameter inflation seen at dissection, but length-based surveillance has never been tested prospectively (Wu 2019, PMID 31526537).
  • Is population or risk-stratified screening (beyond first-degree relatives) justified? Family screening yields 24–33% in FDRs (Mariscalco 2018, PMID 30371227; Abbasciano 2022, PMID 35383466), yet no study has assessed clinical or cost-effectiveness of any screening program (Mariscalco 2018, PMID 30371227).
  • What surveillance interval is optimal between 4.5 and 5.0 cm, where dissection risk has already risen sharply (relative risk ~6,300× vs <3.5 cm) but guidelines allow up to 24-month gaps? (Paruchuri 2015, PMID 25997607; Isselbacher 2022, PMID 36322642).

References

  1. Isselbacher EM, Preventza O, Hamilton Black J, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. Circulation. 2022;146:e334-e482. PMID 36322642. doi:10.1161/CIR.0000000000001106
  2. Goldstein SA, Evangelista A, Abbara S, et al. Multimodality imaging of diseases of the thoracic aorta in adults (ASE/EACVI). J Am Soc Echocardiogr. 2015;28:119-182. PMID 25623219. doi:10.1016/j.echo.2014.11.015
  3. Quint LE, Liu PS, Booher AM, et al. Proximal thoracic aortic diameter measurements at CT: repeatability and reproducibility according to measurement method. Int J Cardiovasc Imaging. 2013;29:479-488. PMID 22864960. doi:10.1007/s10554-012-0102-9
  4. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg. 2002;73:17-27. PMID 11834007. doi:10.1016/s0003-4975(01)03236-2
  5. Coady MA, Rizzo JA, Hammond GL, et al. What is the appropriate size criterion for resection of thoracic aortic aneurysms? J Thorac Cardiovasc Surg. 1997;113:476-491. PMID 9081092. doi:10.1016/S0022-5223(97)70360-X
  6. Davies RR, Kaple RK, Mandapati D, et al. Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. Ann Thorac Surg. 2007;83:1338-1344. PMID 17383337. doi:10.1016/j.athoracsur.2006.10.074
  7. Paruchuri V, Salhab KF, Kuzmik G, et al. Aortic size distribution in the general population: explaining the size paradox in aortic dissection. Cardiology. 2015;131:265-272. PMID 25997607. doi:10.1159/000381281
  8. Mariscalco G, Debiec R, Elefteriades JA, et al. Systematic review of studies that have evaluated screening tests in relatives of patients affected by nonsyndromic thoracic aortic disease. J Am Heart Assoc. 2018;7:e009302. PMID 30371227. doi:10.1161/JAHA.118.009302
  9. Abbasciano RG, Mariscalco G, Barwell J, et al. Evaluating the feasibility of screening relatives of patients affected by nonsyndromic thoracic aortic diseases: the REST study. J Am Heart Assoc. 2022;11:e023741. PMID 35383466. doi:10.1161/JAHA.121.023741
  10. Wu J, Zafar MA, Li Y, et al. Ascending aortic length and risk of aortic adverse events: the neglected dimension. J Am Coll Cardiol. 2019;74:1883-1894. PMID 31526537. doi:10.1016/j.jacc.2019.07.078